APO Research
Talk to an analyst

APO RESEARCH · REPORT

Urological Cancer Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Urological Cancer Drugs Industry Growth and Trends Forecast to 2032

20 December 2025116 pages

Choose your research edition.

Industry ResearchUrological Cancer Drugs Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Urological Cancer Drugs Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Urological Cancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Urological Cancer Drugs Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Urological Cancer Drugs Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Urological Cancer Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Urological Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Urological Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Urological Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Urological Cancer Drugs include Johnson & Johnson, Novartis, Pfizer, GlaxoSmithKline, AstraZeneca, Tolmar Inc, Sanofi S.A, Roche Healthcare and Ipsen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Urological Cancer Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Urological Cancer Drugs market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Urological Cancer Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Urological Cancer Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Urological Cancer Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Urological Cancer Drugs Market by Company

Johnson & Johnson

Novartis

Pfizer

GlaxoSmithKline

AstraZeneca

Tolmar Inc

Sanofi S.A

Roche Healthcare

Ipsen

Indevus Pharmaceuticals Inc

Ferring Pharmaceuticals

Dendreon Corporation

Celgene Corporation

Bristol-Myers Squibb

Astellas

Abbott Laboratories

Urological Cancer Drugs Segment by Type

Tablets

Injection

Urological Cancer Drugs Segment by Application

Bladder Cancer

Testicular Cancer

Prostate Cancer

Kidney Cancer

Others

Urological Cancer Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Urological Cancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Urological Cancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Urological Cancer Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Urological Cancer Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Urological Cancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Tablets Table 2. Major Company of Injection Table 3. Global Urological Cancer Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Urological Cancer Drugs Sales by Type (2021-2026) & (K Units) Table 5. Global Urological Cancer Drugs Sales Market Share in Volume by Type (2021-2026) Table 6. Global Urological Cancer Drugs Sales by Type (2021-2026) & (US$ Million) Table 7. Global Urological Cancer Drugs Sales Market Share in Value by Type (2021-2026) Table 8. Global Urological Cancer Drugs Price by Type (2021-2026) & (US$/Unit) Table 9. Global Urological Cancer Drugs Sales by Type (2027-2032) & (K Units) Table 10. Global Urological Cancer Drugs Sales Market Share in Volume by Type (2027-2032) Table 11. Global Urological Cancer Drugs Sales by Type (2027-2032) & (US$ Million) Table 12. Global Urological Cancer Drugs Sales Market Share in Value by Type (2027-2032) Table 13. Global Urological Cancer Drugs Price by Type (2027-2032) & (US$/Unit) Table 14. North America Urological Cancer Drugs Sales by Type (2021-2026) & (K Units) Table 15. North America Urological Cancer Drugs Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Urological Cancer Drugs Sales by Type (2021-2026) & (K Units) Table 17. Europe Urological Cancer Drugs Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Urological Cancer Drugs Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Urological Cancer Drugs Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Urological Cancer Drugs Sales by Type (2021-2026) & (K Units) Table 21. Latin America Urological Cancer Drugs Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Urological Cancer Drugs Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Urological Cancer Drugs Sales by Type (2021-2026) & (US$ Million) Table 24. Urological Cancer Drugs Industry Trends Table 25. Urological Cancer Drugs Industry Drivers Table 26. Urological Cancer Drugs Industry Opportunities and Challenges Table 27. Urological Cancer Drugs Industry Restraints Table 28. Global Urological Cancer Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Urological Cancer Drugs Revenue Market Share by Company (2021-2026) Table 30. Global Urological Cancer Drugs Sales by Company (2021-2026) & (K Units) Table 31. Global Urological Cancer Drugs Sales Share by Company (2021-2026) Table 32. Global Urological Cancer Drugs Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Urological Cancer Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Urological Cancer Drugs Major Company Production Sites and Headquarters Table 35. Global Urological Cancer Drugs Company, Product Type & Application Table 36. Global Urological Cancer Drugs Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Urological Cancer Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Urological Cancer Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Urological Cancer Drugs Sales by Region (2021-2026) & (K Units) Table 41. Global Urological Cancer Drugs Sales Market Share in Volume by Region (2021-2026) Table 42. Global Urological Cancer Drugs Sales by Region (2021-2026) & (US$ Million) Table 43. Global Urological Cancer Drugs Sales Market Share in Value by Region (2021-2026) Table 44. Global Urological Cancer Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Urological Cancer Drugs Sales by Region (2027-2032) & (K Units) Table 46. Global Urological Cancer Drugs Sales Market Share in Volume by Region (2027-2032) Table 47. Global Urological Cancer Drugs Sales by Region (2027-2032) & (US$ Million) Table 48. Global Urological Cancer Drugs Sales Market Share in Value by Region (2027-2032) Table 49. Global Urological Cancer Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Urological Cancer Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Urological Cancer Drugs Sales by Application (2021-2026) & (K Units) Table 52. Global Urological Cancer Drugs Sales Market Share in Volume by Application (2021-2026) Table 53. Global Urological Cancer Drugs Sales by Application (2021-2026) & (US$ Million) Table 54. Global Urological Cancer Drugs Sales Market Share in Value by Application (2021-2026) Table 55. Global Urological Cancer Drugs Price by Application (2021-2026) & (US$/Unit) Table 56. Global Urological Cancer Drugs Sales by Application (2027-2032) & (K Units) Table 57. Global Urological Cancer Drugs Sales Market Share in Volume by Application (2027-2032) Table 58. Global Urological Cancer Drugs Sales by Application (2027-2032) & (US$ Million) Table 59. Global Urological Cancer Drugs Sales Market Share in Value by Application (2027-2032) Table 60. Global Urological Cancer Drugs Price by Application (2027-2032) & (US$/Unit) Table 61. North America Urological Cancer Drugs Sales by Application (2021-2026) & (K Units) Table 62. North America Urological Cancer Drugs Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Urological Cancer Drugs Sales by Application (2021-2026) & (K Units) Table 64. Europe Urological Cancer Drugs Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Urological Cancer Drugs Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Urological Cancer Drugs Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Urological Cancer Drugs Sales by Application (2021-2026) & (K Units) Table 68. Latin America Urological Cancer Drugs Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Urological Cancer Drugs Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Urological Cancer Drugs Sales by Application (2021-2026) & (US$ Million) Table 71. Johnson & Johnson Company Information Table 72. Johnson & Johnson Business Overview Table 73. Johnson & Johnson Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Johnson & Johnson Urological Cancer Drugs Product Portfolio Table 75. Johnson & Johnson Recent Development Table 76. Novartis Company Information Table 77. Novartis Business Overview Table 78. Novartis Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Novartis Urological Cancer Drugs Product Portfolio Table 80. Novartis Recent Development Table 81. Pfizer Company Information Table 82. Pfizer Business Overview Table 83. Pfizer Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Pfizer Urological Cancer Drugs Product Portfolio Table 85. Pfizer Recent Development Table 86. GlaxoSmithKline Company Information Table 87. GlaxoSmithKline Business Overview Table 88. GlaxoSmithKline Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. GlaxoSmithKline Urological Cancer Drugs Product Portfolio Table 90. GlaxoSmithKline Recent Development Table 91. AstraZeneca Company Information Table 92. AstraZeneca Business Overview Table 93. AstraZeneca Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. AstraZeneca Urological Cancer Drugs Product Portfolio Table 95. AstraZeneca Recent Development Table 96. Tolmar Inc Company Information Table 97. Tolmar Inc Business Overview Table 98. Tolmar Inc Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Tolmar Inc Urological Cancer Drugs Product Portfolio Table 100. Tolmar Inc Recent Development Table 101. Sanofi S.A Company Information Table 102. Sanofi S.A Business Overview Table 103. Sanofi S.A Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Sanofi S.A Urological Cancer Drugs Product Portfolio Table 105. Sanofi S.A Recent Development Table 106. Roche Healthcare Company Information Table 107. Roche Healthcare Business Overview Table 108. Roche Healthcare Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Roche Healthcare Urological Cancer Drugs Product Portfolio Table 110. Roche Healthcare Recent Development Table 111. Ipsen Company Information Table 112. Ipsen Business Overview Table 113. Ipsen Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Ipsen Urological Cancer Drugs Product Portfolio Table 115. Ipsen Recent Development Table 116. Indevus Pharmaceuticals Inc Company Information Table 117. Indevus Pharmaceuticals Inc Business Overview Table 118. Indevus Pharmaceuticals Inc Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Indevus Pharmaceuticals Inc Urological Cancer Drugs Product Portfolio Table 120. Indevus Pharmaceuticals Inc Recent Development Table 121. Ferring Pharmaceuticals Company Information Table 122. Ferring Pharmaceuticals Business Overview Table 123. Ferring Pharmaceuticals Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Ferring Pharmaceuticals Urological Cancer Drugs Product Portfolio Table 125. Ferring Pharmaceuticals Recent Development Table 126. Dendreon Corporation Company Information Table 127. Dendreon Corporation Business Overview Table 128. Dendreon Corporation Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Dendreon Corporation Urological Cancer Drugs Product Portfolio Table 130. Dendreon Corporation Recent Development Table 131. Celgene Corporation Company Information Table 132. Celgene Corporation Business Overview Table 133. Celgene Corporation Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Celgene Corporation Urological Cancer Drugs Product Portfolio Table 135. Celgene Corporation Recent Development Table 136. Bristol-Myers Squibb Company Information Table 137. Bristol-Myers Squibb Business Overview Table 138. Bristol-Myers Squibb Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Bristol-Myers Squibb Urological Cancer Drugs Product Portfolio Table 140. Bristol-Myers Squibb Recent Development Table 141. Astellas Company Information Table 142. Astellas Business Overview Table 143. Astellas Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Astellas Urological Cancer Drugs Product Portfolio Table 145. Astellas Recent Development Table 146. Abbott Laboratories Company Information Table 147. Abbott Laboratories Business Overview Table 148. Abbott Laboratories Urological Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. Abbott Laboratories Urological Cancer Drugs Product Portfolio Table 150. Abbott Laboratories Recent Development Table 151. North America Urological Cancer Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 152. North America Urological Cancer Drugs Sales by Country (2021-2026) & (K Units) Table 153. North America Urological Cancer Drugs Sales Market Share by Country (2021-2026) Table 154. North America Urological Cancer Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 155. North America Urological Cancer Drugs Sales Market Share Forecast by Country (2027-2032) Table 156. North America Urological Cancer Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. North America Urological Cancer Drugs Market Size by Country (2021-2026) & (US$ Million) Table 158. North America Urological Cancer Drugs Market Share by Country (2021-2026) Table 159. North America Urological Cancer Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. North America Urological Cancer Drugs Market Share Forecast by Country (2027-2032) Table 161. Europe Urological Cancer Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 162. Europe Urological Cancer Drugs Sales by Country (2021-2026) & (K Units) Table 163. Europe Urological Cancer Drugs Sales Market Share by Country (2021-2026) Table 164. Europe Urological Cancer Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 165. Europe Urological Cancer Drugs Sales Market Share Forecast by Country (2027-2032) Table 166. Europe Urological Cancer Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. Europe Urological Cancer Drugs Market Size by Country (2021-2026) & (US$ Million) Table 168. Europe Urological Cancer Drugs Market Share by Country (2021-2026) Table 169. Europe Urological Cancer Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. Europe Urological Cancer Drugs Market Share Forecast by Country (2027-2032) Table 171. Asia-Pacific Urological Cancer Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 172. Asia-Pacific Urological Cancer Drugs Sales by Country (2021-2026) & (K Units) Table 173. Asia-Pacific Urological Cancer Drugs Sales Market Share by Country (2021-2026) Table 174. Asia-Pacific Urological Cancer Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 175. Asia-Pacific Urological Cancer Drugs Sales Market Share Forecast by Country (2027-2032) Table 176. Asia-Pacific Urological Cancer Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 177. Asia-Pacific Urological Cancer Drugs Market Size by Country (2021-2026) & (US$ Million) Table 178. Asia-Pacific Urological Cancer Drugs Market Share by Country (2021-2026) Table 179. Asia-Pacific Urological Cancer Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 180. Asia-Pacific Urological Cancer Drugs Market Share Forecast by Country (2027-2032) Table 181. Latin America Urological Cancer Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 182. Latin America Urological Cancer Drugs Sales by Country (2021-2026) & (K Units) Table 183. Latin America Urological Cancer Drugs Sales Market Share by Country (2021-2026) Table 184. Latin America Urological Cancer Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 185. Latin America Urological Cancer Drugs Sales Market Share Forecast by Country (2027-2032) Table 186. Latin America Urological Cancer Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 187. Latin America Urological Cancer Drugs Market Size by Country (2021-2026) & (US$ Million) Table 188. Latin America Urological Cancer Drugs Market Share by Country (2021-2026) Table 189. Latin America Urological Cancer Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 190. Latin America Urological Cancer Drugs Market Share Forecast by Country (2027-2032) Table 191. Middle East and Africa Urological Cancer Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 192. Middle East and Africa Urological Cancer Drugs Sales by Country (2021-2026) & (K Units) Table 193. Middle East and Africa Urological Cancer Drugs Sales Market Share by Country (2021-2026) Table 194. Middle East and Africa Urological Cancer Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 195. Middle East and Africa Urological Cancer Drugs Sales Market Share Forecast by Country (2027-2032) Table 196. Middle East and Africa Urological Cancer Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 197. Middle East and Africa Urological Cancer Drugs Market Size by Country (2021-2026) & (US$ Million) Table 198. Middle East and Africa Urological Cancer Drugs Market Share by Country (2021-2026) Table 199. Middle East and Africa Urological Cancer Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 200. Middle East and Africa Urological Cancer Drugs Market Share Forecast by Country (2027-2032) Table 201. Key Raw Materials Table 202. Raw Materials Key Suppliers Table 203. Urological Cancer Drugs Distributors List Table 204. Urological Cancer Drugs Customers List Table 205. Research Programs/Design for This Report Table 206. Authors List of This Report Table 207. Secondary Sources Table 208. Primary Sources List of Figures Figure 1. Urological Cancer Drugs Image Figure 2. Global Urological Cancer Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Urological Cancer Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Urological Cancer Drugs Sales (2021-2032) & (K Units) Figure 5. Tablets Image Figure 6. Global Tablets Sales YoY Growth (2021-2032) & (K Units) Figure 7. Injection Image Figure 8. Global Injection Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Urological Cancer Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Urological Cancer Drugs Market Share by Type 2025 VS 2032 Figure 11. North America Urological Cancer Drugs Sales Market Share in Volume by Type in 2025 Figure 12. North America Urological Cancer Drugs Sales Market Share in Value by Type in 2025 Figure 13. Europe Urological Cancer Drugs Sales Market Share in Volume by Type in 2025 Figure 14. Europe Urological Cancer Drugs Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Urological Cancer Drugs Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Urological Cancer Drugs Sales Market Share in Value by Type in 2025 Figure 17. Latin America Urological Cancer Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Urological Cancer Drugs Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Urological Cancer Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Urological Cancer Drugs Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Urological Cancer Drugs Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Bladder Cancer Image Figure 24. Global Bladder Cancer Sales YoY Growth (2021-2032) & (K Units) Figure 25. Testicular Cancer Image Figure 26. Global Testicular Cancer Sales YoY Growth (2021-2032) & (K Units) Figure 27. Prostate Cancer Image Figure 28. Global Prostate Cancer Sales YoY Growth (2021-2032) & (K Units) Figure 29. Kidney Cancer Image Figure 30. Global Kidney Cancer Sales YoY Growth (2021-2032) & (K Units) Figure 31. Others Image Figure 32. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 33. Global Urological Cancer Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Urological Cancer Drugs Market Share by Application 2025 VS 2032 Figure 35. North America Urological Cancer Drugs Sales Market Share in Volume by Application in 2025 Figure 36. North America Urological Cancer Drugs Sales Market Share in Value by Application in 2025 Figure 37. Europe Urological Cancer Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Europe Urological Cancer Drugs Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Urological Cancer Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Urological Cancer Drugs Sales Market Share in Value by Application in 2025 Figure 41. Latin America Urological Cancer Drugs Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Urological Cancer Drugs Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Urological Cancer Drugs Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Urological Cancer Drugs Sales Market Share in Value by Application in 2025 Figure 45. North America Urological Cancer Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. North America Urological Cancer Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Urological Cancer Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Urological Cancer Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Urological Cancer Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Europe Urological Cancer Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Urological Cancer Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Urological Cancer Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Urological Cancer Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Asia-Pacific Urological Cancer Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Urological Cancer Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Urological Cancer Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Urological Cancer Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Latin America Urological Cancer Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Urological Cancer Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Urological Cancer Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Urological Cancer Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Middle East and Africa Urological Cancer Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Urological Cancer Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Urological Cancer Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Urological Cancer Drugs Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Urological Cancer Drugs Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Tablets
  • Injection
Applications
  • Bladder Cancer
  • Testicular Cancer
  • Prostate Cancer
  • Kidney Cancer
  • Others
Companies covered
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • GlaxoSmithKline
  • AstraZeneca
  • Tolmar Inc
  • Sanofi S.A
  • Roche Healthcare
  • Ipsen
  • Indevus Pharmaceuticals Inc
  • Ferring Pharmaceuticals
  • Dendreon Corporation
  • Celgene Corporation
  • Bristol-Myers Squibb
  • Astellas
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Urological Cancer Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Urological Cancer Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Urological Cancer Drugs Market by Type
  6. 1.3.1 Tablets
  7. 1.3.2 Injection
  8. 1.4 Global Urological Cancer Drugs Market Size by Type
  9. 1.4.1 Global Urological Cancer Drugs Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Urological Cancer Drugs Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Urological Cancer Drugs Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Urological Cancer Drugs Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Urological Cancer Drugs Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Urological Cancer Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Urological Cancer Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Urological Cancer Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Urological Cancer Drugs Industry Trends
  2. 2.2 Urological Cancer Drugs Industry Drivers
  3. 2.3 Urological Cancer Drugs Industry Opportunities and Challenges
  4. 2.4 Urological Cancer Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Urological Cancer Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Urological Cancer Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Urological Cancer Drugs Price (2021-2026)
  4. 3.4 Global Urological Cancer Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Urological Cancer Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Urological Cancer Drugs Company, Product Type & Application
  7. 3.7 Global Urological Cancer Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Urological Cancer Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Urological Cancer Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Urological Cancer Drugs Tier 1, Tier 2, and Tier 3
4 Urological Cancer Drugs Regional Status and Outlook
  1. 4.1 Global Urological Cancer Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Urological Cancer Drugs Historic Market Size by Region
  3. 4.2.1 Global Urological Cancer Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Urological Cancer Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Urological Cancer Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Urological Cancer Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Urological Cancer Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Urological Cancer Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Urological Cancer Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Urological Cancer Drugs by Application
  1. 5.1 Urological Cancer Drugs Market by Application
  2. 5.1.1 Bladder Cancer
  3. 5.1.2 Testicular Cancer
  4. 5.1.3 Prostate Cancer
  5. 5.1.4 Kidney Cancer
  6. 5.1.5 Others
  7. 5.2 Global Urological Cancer Drugs Market Size by Application
  8. 5.2.1 Global Urological Cancer Drugs Market Size Overview by Application (2021-2032)
  9. 5.2.2 Global Urological Cancer Drugs Historic Market Size Review by Application (2021-2026)
  10. 5.2.3 Global Urological Cancer Drugs Forecasted Market Size by Application (2027-2032)
  11. 5.3 Key Regions Market Size by Application
  12. 5.3.1 North America Urological Cancer Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.2 Europe Urological Cancer Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.3 Asia-Pacific Urological Cancer Drugs Sales Breakdown by Application (2021-2026)
  15. 5.3.4 South America Urological Cancer Drugs Sales Breakdown by Application (2021-2026)
  16. 5.3.5 Middle East and Africa Urological Cancer Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Johnson & Johnson
  2. 6.1.1 Johnson & Johnson Company Information
  3. 6.1.2 Johnson & Johnson Business Overview
  4. 6.1.3 Johnson & Johnson Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Johnson & Johnson Urological Cancer Drugs Product Portfolio
  6. 6.1.5 Johnson & Johnson Recent Developments
  7. 6.2 Novartis
  8. 6.2.1 Novartis Company Information
  9. 6.2.2 Novartis Business Overview
  10. 6.2.3 Novartis Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Novartis Urological Cancer Drugs Product Portfolio
  12. 6.2.5 Novartis Recent Developments
  13. 6.3 Pfizer
  14. 6.3.1 Pfizer Company Information
  15. 6.3.2 Pfizer Business Overview
  16. 6.3.3 Pfizer Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Pfizer Urological Cancer Drugs Product Portfolio
  18. 6.3.5 Pfizer Recent Developments
  19. 6.4 GlaxoSmithKline
  20. 6.4.1 GlaxoSmithKline Company Information
  21. 6.4.2 GlaxoSmithKline Business Overview
  22. 6.4.3 GlaxoSmithKline Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 GlaxoSmithKline Urological Cancer Drugs Product Portfolio
  24. 6.4.5 GlaxoSmithKline Recent Developments
  25. 6.5 AstraZeneca
  26. 6.5.1 AstraZeneca Company Information
  27. 6.5.2 AstraZeneca Business Overview
  28. 6.5.3 AstraZeneca Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 AstraZeneca Urological Cancer Drugs Product Portfolio
  30. 6.5.5 AstraZeneca Recent Developments
  31. 6.6 Tolmar Inc
  32. 6.6.1 Tolmar Inc Company Information
  33. 6.6.2 Tolmar Inc Business Overview
  34. 6.6.3 Tolmar Inc Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Tolmar Inc Urological Cancer Drugs Product Portfolio
  36. 6.6.5 Tolmar Inc Recent Developments
  37. 6.7 Sanofi S.A
  38. 6.7.1 Sanofi S.A Company Information
  39. 6.7.2 Sanofi S.A Business Overview
  40. 6.7.3 Sanofi S.A Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Sanofi S.A Urological Cancer Drugs Product Portfolio
  42. 6.7.5 Sanofi S.A Recent Developments
  43. 6.8 Roche Healthcare
  44. 6.8.1 Roche Healthcare Company Information
  45. 6.8.2 Roche Healthcare Business Overview
  46. 6.8.3 Roche Healthcare Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Roche Healthcare Urological Cancer Drugs Product Portfolio
  48. 6.8.5 Roche Healthcare Recent Developments
  49. 6.9 Ipsen
  50. 6.9.1 Ipsen Company Information
  51. 6.9.2 Ipsen Business Overview
  52. 6.9.3 Ipsen Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Ipsen Urological Cancer Drugs Product Portfolio
  54. 6.9.5 Ipsen Recent Developments
  55. 6.10 Indevus Pharmaceuticals Inc
  56. 6.10.1 Indevus Pharmaceuticals Inc Company Information
  57. 6.10.2 Indevus Pharmaceuticals Inc Business Overview
  58. 6.10.3 Indevus Pharmaceuticals Inc Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Indevus Pharmaceuticals Inc Urological Cancer Drugs Product Portfolio
  60. 6.10.5 Indevus Pharmaceuticals Inc Recent Developments
  61. 6.11 Ferring Pharmaceuticals
  62. 6.11.1 Ferring Pharmaceuticals Company Information
  63. 6.11.2 Ferring Pharmaceuticals Business Overview
  64. 6.11.3 Ferring Pharmaceuticals Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Ferring Pharmaceuticals Urological Cancer Drugs Product Portfolio
  66. 6.11.5 Ferring Pharmaceuticals Recent Developments
  67. 6.12 Dendreon Corporation
  68. 6.12.1 Dendreon Corporation Company Information
  69. 6.12.2 Dendreon Corporation Business Overview
  70. 6.12.3 Dendreon Corporation Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Dendreon Corporation Urological Cancer Drugs Product Portfolio
  72. 6.12.5 Dendreon Corporation Recent Developments
  73. 6.13 Celgene Corporation
  74. 6.13.1 Celgene Corporation Company Information
  75. 6.13.2 Celgene Corporation Business Overview
  76. 6.13.3 Celgene Corporation Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Celgene Corporation Urological Cancer Drugs Product Portfolio
  78. 6.13.5 Celgene Corporation Recent Developments
  79. 6.14 Bristol-Myers Squibb
  80. 6.14.1 Bristol-Myers Squibb Company Information
  81. 6.14.2 Bristol-Myers Squibb Business Overview
  82. 6.14.3 Bristol-Myers Squibb Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Bristol-Myers Squibb Urological Cancer Drugs Product Portfolio
  84. 6.14.5 Bristol-Myers Squibb Recent Developments
  85. 6.15 Astellas
  86. 6.15.1 Astellas Company Information
  87. 6.15.2 Astellas Business Overview
  88. 6.15.3 Astellas Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Astellas Urological Cancer Drugs Product Portfolio
  90. 6.15.5 Astellas Recent Developments
  91. 6.16 Abbott Laboratories
  92. 6.16.1 Abbott Laboratories Company Information
  93. 6.16.2 Abbott Laboratories Business Overview
  94. 6.16.3 Abbott Laboratories Urological Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Abbott Laboratories Urological Cancer Drugs Product Portfolio
  96. 6.16.5 Abbott Laboratories Recent Developments
7 North America by Country
  1. 7.1 North America Urological Cancer Drugs Sales by Country
  2. 7.1.1 North America Urological Cancer Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Urological Cancer Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Urological Cancer Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Urological Cancer Drugs Market Size by Country
  6. 7.2.1 North America Urological Cancer Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Urological Cancer Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Urological Cancer Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Urological Cancer Drugs Sales by Country
  2. 8.1.1 Europe Urological Cancer Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Urological Cancer Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Urological Cancer Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Urological Cancer Drugs Market Size by Country
  6. 8.2.1 Europe Urological Cancer Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Urological Cancer Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Urological Cancer Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Urological Cancer Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Urological Cancer Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Urological Cancer Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Urological Cancer Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Urological Cancer Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Urological Cancer Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Urological Cancer Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Urological Cancer Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Urological Cancer Drugs Sales by Country
  2. 10.1.1 South America Urological Cancer Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Urological Cancer Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Urological Cancer Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Urological Cancer Drugs Market Size by Country
  6. 10.2.1 South America Urological Cancer Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Urological Cancer Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Urological Cancer Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Urological Cancer Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Urological Cancer Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Urological Cancer Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Urological Cancer Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Urological Cancer Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Urological Cancer Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Urological Cancer Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Urological Cancer Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Urological Cancer Drugs Value Chain Analysis
  2. 12.1.1 Urological Cancer Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Urological Cancer Drugs Production Mode & Process
  7. 12.2 Urological Cancer Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Urological Cancer Drugs Distributors
  10. 12.2.3 Urological Cancer Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst